Andrade, Luiz Flavio
Ludwig, Kristina
Goni, Juan Manuel Ramos
Oppe, Mark
de Pouvourville, Gérard http://orcid.org/0000-0002-5941-6823
Funding for this research was provided by:
EuroQol (EQ 20170510)
AbbVie (1768005)
Allergan (P-2018-7046)
Amgen (FR 17 10 507)
Biogen (1868106)
BMS (1768053)
GSK (Contract 05/07/2018)
Janssen Cilag (1768065)
MSD (1768064)
Lilly (Contract 11/24/2017)
Novartis (1768051)
Roche (Contract 01/08/2018)
Sanofi (1768122)
Article History
First Online: 8 January 2020
Compliance with Ethical Standards
:
: This study was funded by EuroQol (EQ 20170510), as well as Abbvie (1768005), Allergan (P-2018-7046), Amgen (FR 17 10 507), Biogen (1868106), BMS (1768053), GSK (Contract 05/07/2018), Janssen Cilag (1768065), MSD, Lilly (Contract 11/24/2017), Novartis (1768051), Roche (Contract 01/08/2018), and Sanofi (1768122). The ESSEC was the recipient of funds. Funding was unrestricted and companies have no claims on the data and the results.
: Gérard de Pouvourville was Full Professor at the ESSEC Business School at the time of this study. He has been, and is, a regular consultant for the funding companies, as a member of advisory boards on cost-effectiveness analyses. The ESSEC has also received funding to perform cost-effectiveness analysis. None of the existing funding has been related to developing value sets for quality-of-life questionnaires. The ESSEC is currently funded to perform a survey on the quality of life of French inflammatory bowel disease patients using EQ-5D-5L. The funding sources were Euroqol, Amgen, MSD, Janssen Cilag and Biogaran, through unrestricted research grants. Luiz Andrade was a research assistant at the time of the study and was employed by the ESSEC. He has no direct financial conflicts of interest. Kristina Ludwig worked as a freelancer for the EuroQol Research Foundation during the data collection phase of the study and has received research grants from the Foundation to conduct methodological research. She has received no direct payment from industrial sponsors for this study. As a collaborator of EuroQol and the main investigator of the German Value Set, she supports the EQ-5D-5L and the methodological choices made by the Foundation. Mark Oppe was an employee of the EuroQol Research Foundation at the time of the study, but now works for Axentiva Solutions, a consulting company based in Spain. He was a main contributor to the development of the EQ-5D-5L valuation methodology, specifically for the cTTO protocol, the Quality Control module, and the development of the hybrid methodology. Juan Manuel Ramos Goni is a member of EuroQol and founder of Axentiva Solutions. He has received no direct payment from industry sponsors for the French study. He also contributed to the development of the EQ-5D-5L valuation methodology, specifically for the development of the hybrid methodology.
: This study has been declared to the Commission Nationale Informatique et Liberté (CNIL) as MR003 type research, under number 225070 v 0. The research does not come under the general field of “research organized to be applied to the human being with the aim of the development of biologic or medical knowledge” and did not require submission to a Committee for the Protection of Persons (CPP). Informed consent of respondents was requested before the interview started, and the interview process could not start if potential respondents refused to participate.